Sanofi: presents results of UCS study

(CercleFinance.com) - Sanofi announces that Dupixent provides significant improvements in pruritus and urticaria, as confirmed by a Phase III study in patients with chronic spontaneous urticaria (CSU).


CSU is a chronic skin disease that causes sudden eruptions of disabling urticarial plaques and persistent itching that can impact quality of life.

This second pivotal study in biologic drug-naïve patients confirms the results of the CUPID-A study, met its primary and primary secondary endpoints, and showed that treatment with Dupixent resulted in an almost 50% reduction in pruritus and urticaria activity scores, compared to placebo.

In the USA, over 300,000 people suffer from chronic spontaneous urticaria (CSU) inadequately controlled by antihistamines.

These data will motivate a new regulatory submission in the USA by the end of the year. If approved, Dupixent will be the first targeted drug for the treatment of SCU in ten years.

Copyright (c) 2024 CercleFinance.com. All rights reserved.